Publications

Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C. A three-gene model to robustly identify breast cancer molecular subtypes. Journal of the National Cancer Institute. 2012:311–325.

Desmedt C, A. DL, de Azambuja E, Larsimont D, B. H-K, J. S, Delaloge S, Duhem C, Kains JP, Carly B, et al. Multifactorial Approach to Predicting Resistance to Anthracyclines. Journal Clinical Oncology [Internet]. 2011.

Bontempi G, Haibe-Kains B, Desmedt C, Sotiriou C, Quackenbush J. Multiple-input multiple-output causal strategies for gene selection. BMC bioinformatics. 2011:458.

Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nature Medecine. 2010.

Juul N, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans FW, Desmedt C, et al. Evaluation of an RNA interference screen-derived mitotic and ceramide pathway meta- gene in paclitaxel-treated primary ER-/PR-/ERBB2- breast cancer: a retrospective analysis of five clinical trials. Lancet Oncology. 2010.

Haibe-Kains B, Desmedt C, Rothé F, Piccart M, Sotiriou C, Bontempi G. A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biology. 2010.

Toussaint J, Durbecq V, Altintas S, Doriath V, Rouas G, Paesmans M, Bedard P, Haibe-Kains B, Tjalma WA, Larsimont D, et al. Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS ONE. 2010.

Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans FW, Bardelli A, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor positive breast cancer. PNAS. 2010.

Haibe-Kains B, Culhane AC, Desmedt C, Bontempi G, Quackenbush J, Sotiriou C. Robustness of breast cancer molecular subtypes identification. Annals of Oncology. 2010.

Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Bardelli A, Gillett C, Ellis P, Piccart-Gebhart MJ, Phillips WA, McArthur GA, et al. Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers. J Clin Oncol (Meeting Abstracts). 2009:533-.

Desmedt C, Giobbie-Hurder A, Neven P, Paridaens R, Christiaens MR, Smeets A, Lallemand F, Haibe-Kains B, Viale G, Gelber R, et al. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Medical Genomics. 2009:40.

Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, et al. Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer. J Clin Oncol. 2009:3185-3191.

Toussaint J, Sieuwerts A, Haibe-Kains B, Desmedt C, Rouas G, Harris A, Larsimont D, Piccart M, Foekens J, Durbecq V, et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics. 2009:424.

Ravoet M, Sibille C, Gu C, Libin M, Haibe-Kains B, Sotiriou C, Goldman M, Roufosse F, Willard-Gallo K. Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood. 2009:blood-2008-08-175091.

Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. Clin Cancer Res [Internet]. 2008:5158-5165.

Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?. Bioinformatics [Internet]. 2008:2200-2208.

Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, van't Veer L, Piccart M, Bontempi G, Sotiriou C. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics [Internet]. 2008:394.

Haibe-Kains B, Desmedt C, Loi S, Delorenzi M, Sotiriou C, Bontempi G. Computational Intelligence in Clinical Oncology : Lessons Learned from an Analysis of a Clinical Study. In: Applications of Computational Intelligence in Biology. Vol. 122. Applications of Computational Intelligence in Biology. ; 2008. p. 237-268.

Sotiriou C, C.Equeter, Ouriaghli EF, Haibe-Kains B, Durbecq V, Larsimont D, Igniatiadis M, Desmedt C, Willard-Gallo K, Piccart MJ, et al. Correlation of gene expression analysis of tumor-infiltrating CD4+ cells with immune function and survival according to different breast cancer (BC) molecular subtypes. In: of Oncology JC ASCO Annual Meeting Proceedings. Vol. 20. ASCO Annual Meeting Proceedings. ; 2008. p. .

Journe F, Durbecq V, Haibe-Kains B, Chaboteaux C, Rouas G, Laurent G, Larsimont D, Piccart MJ, Body JJ, Sotiriou C, et al. Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen. European Journal of Cancer Supplements. 2008:112.

Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Research [Internet]. 2008:R65.

Toussaint J, Sieuwerts A, Durbecq V, Haibe-Kains B, Berns E, Harris AL, Larsimont D, Piccart M, Foekens J, Sotiriou C, et al. Molecular qRT-PCR grade index: a new tool for breast cancer (BC) patient grading improvement. European Journal of Cancer Supplements. 2008:140.

Journe F, Durbecq V, Chaboteaux C, Rouas G, Haibe-Kains B, IdBoufker H, Laurent G, Sotiriou C, Larsimont D, Body JJ, et al. OC3. Farnesoid X receptor (FXR): A new marker for the prediction of bone metastases in breast cancer. Cancer treatment reviews [Internet]. 2008:50.

Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt A, Gillet C, Ellis P, Ryder K, Reid J, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics [Internet]. 2008:239.

Sotiriou C, Desmedt C, Haibe-Kains B, Harris A, Larsimont D, Buyse M, Wirapati P, Delorenzi M, Bontempi G, Piccart MJ, et al. Biological mechanisms that trigger breast cancer (BC) tumor progresion are molecular subtype dependent.